Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase NA 1Phase 3 1Phase 1 1

Status

Unknown 1Suspended 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 10Lymphoid 5Thoracic 2Dermatologic 2Sarcoma 1Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 700Lung Neoplasms 298Small Cell Lung Carcinoma 149Colorectal Neoplasms 114Melanoma 106Neoplasms 93Breast Neoplasms 93Ovarian Neoplasms 92Neoplasm Metastasis 86Squamous Cell Carcinoma of Head and Neck 83Stomach Neoplasms 81Pancreatic Neoplasms 79Carcinoma, Renal Cell 66Triple Negative Breast Neoplasms 63Esophageal Neoplasms 51Endometrial Neoplasms 48Uterine Cervical Neoplasms 47Head and Neck Neoplasms 47Mesothelioma 42Mesothelioma, Malignant 41Sarcoma 40Prostatic Neoplasms 36Urinary Bladder Neoplasms 34Colonic Neoplasms 32Carcinoma, Transitional Cell 32Carcinoma, Hepatocellular 31Adenocarcinoma of Lung 31Carcinoma 26Recurrence 21Thyroid Neoplasms 20

Interventions

aflutinib 1Monatide (IMS 3015) 1Biological Assay 1AST5902 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm, Residual × Thoracic × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Peking University People's Hospital

Phase 1/2 Unknown
50 enrolled
Thoracic

Adenocarcinoma of Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡